Heme oxygenase‐1 in growth control and its clinical application to vascular disease
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Heme oxygenase‐1 (HO‐1) catalyzes the degradation of heme to carbon monoxide (CO), iron, and biliverdin. Biliverdin is subsequently metabolized to bilirubin by the enzyme biliverdin reductase. Although interest in HO‐1 originally centered on its heme‐degrading function, recent findings indicate that HO‐1 exerts other biologically important actions. Emerging evidence suggests that HO‐1 plays a critical role in growth regulation. Deletion of the HO‐1 gene or inhibition of HO‐1 activity results in growth retardation and impaired fetal development, whereas HO‐1 overexpression increases body size. Although the mechanisms responsible for the growth promoting properties of HO‐1 are not well established, HO‐1 can indirectly influence growth by regulating the synthesis of growth factors and by modulating the delivery of oxygen or nutrients to specific target tissues. In addition, HO‐1 exerts important effects on critical determinants of tissue size, including cell proliferation, apoptosis, and hypertrophy. However, the actions of HO‐1 are highly variable and may reflect a role for HO‐1 in maintaining tissue homeostasis. Considerable evidence supports a crucial role for HO‐1 in blocking the growth of vascular smooth muscle cells (SMCs). This antiproliferative effect of HO‐1 is mediated primarily via the release of CO, which inhibits vascular SMC growth via multiple pathways. Pharmacologic or genetic approaches targeting HO‐1 or CO to the blood vessel wall may represent a promising, novel therapeutic approach in treating vascular proliferative disorders. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase.
Tenhunen, R., Marver, H. S., & Schmid, R. (1968) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.61.2.748 · Cited by 1,803
Heme oxygenase: Function, multiplicity, regulatory mechanisms, and clinical applications
Maines, M. D. (1988) · The FASEB Journal · doi:10.1096/fasebj.2.10.3290025 · Cited by 1,707
Heme oxygenase 1 is required for mammalian iron reutilization
Poss, K. D., & Tonegawa, S. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10919 · Cited by 1,016
Carbon Monoxide Generated by Heme Oxygenase 1 Suppresses Endothelial Cell Apoptosis
Brouard, S., Otterbein, L. E., Anrather, J., Tobiasch, E., Bach, F. H., Choi, A. M. K., & Soares, M. P. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1015 · Cited by 984 · cited 20×
“In ECs, the antiapoptotic action of CO results from the activation of the p38 MAPK while the activation of soluble guanylate cyclase contributes to the inhibition of apoptosis in vascular SMCs (Brouard et al., 2000; Liu et al., 2002b).”
BackgroundInfluentialStone, J. R., & Marletta, M. A. (1994) · Biochemistry · doi:10.1021/bi00184a036 · Cited by 647 · cited 1×
“CO activates both crude and purified preparations of soluble guanylate cyclase and elevates cGMP levels in vascular SMCs (Ramos et al., 1989; Brune et al., 1990; Stone and Marletta, 1994; Christodoulides et al., 1995; Morita et al., 1995).”
Background
Cited by
How Many Transcription Factors Does It Take to Turn On the Heme Oxygenase-1 Gene?
Alam, J., & Cook, J. L. (2007) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2006-0340tr · Cited by 375
A Review of Therapeutic Effects of Curcumin
Noorafshan, A., & Ashkani-Esfahani, S. (2013) · Current Pharmaceutical Design · doi:10.2174/138161213805289273 · Cited by 317
Therapeutic applications of carbon monoxide-releasing molecules
Motterlini, R., Mann, B. E., & Foresti, R. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.11.1305 · Cited by 315
Heme oxygenase-1: A provenance for cytoprotective pathways in the kidney and other tissues
Nath, K. A. (2006) · Kidney International · doi:10.1038/sj.ki.5001565 · Cited by 300
Heme oxygenase-1 and neurodegeneration: expanding frontiers of engagement
Schipper, H. M., Song, W., Zukor, H., Hascalovici, J. R., & Zeligman, D. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06160.x · Cited by 298
“The successful manipulation of tissue HO activity for clinical purposes, as considered by several laboratories (Dennery 2000; Scapagnini et al. 2002; Durante 2003; Otterbein et al. 2003; Abraham and Kappas 2008; Syapin 2008) including our own (Schipper 2004a,b; Received March 9, 2009; revised…”
MethodThe protective role of curcumin in cardiovascular diseases
Wongcharoen, W., & Phrommintikul, A. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2009.01.073 · Cited by 292
Berberat, P. O., Dambrauskas, Z., Gulbinas, A., Giese, T., Giese, N., Künzli, B., Autschbach, F., Meuer, S., Büchler, M. W., & Friess, H. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2159 · Cited by 263
Taillé, C., El-Benna, J., Lanone, S., Boczkowski, J., & Motterlini, R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503512200 · Cited by 246
Choi, K. M., Gibbons, S. J., Nguyen, T. V., Stoltz, G. J., Lurken, M. S., Ordog, T., Szurszewski, J. H., & Farrugia, G. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.003 · Cited by 239
Pendrak, M. L., Chao, M. P., Yan, S. S., & Roberts, D. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311550200 · Cited by 97
Metadata
- Authors
- Durante, W.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2003-03-27
- Volume
- 195
- Issue
- 3
- Pages
- 373-382
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2014002468
- Cited by
- 153
- References
- 5
- FWCI
- 6.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.